Haemonetics Corp HAE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
-
Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
-
New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths
-
Martin Madaus Elected to Haemonetics Board of Directors
-
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
Trading Information
- Previous Close Price
- $104.37
- Day Range
- $103.61–105.70
- 52-Week Range
- $47.75–110.45
- Bid/Ask
- $70.00 / $110.59
- Shares Outstanding
- 45.50M
- Market Cap
- $4.76B
- Volume/Avg
- 328,573 / 691,642
Key Statistics
- Price/Earnings (Normalized)
- 20.83
- Price/Sales
- 3.60
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 3.69%
Company Profile
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 3,009
- Website
- https://www.haemonetics.com
Competitors
Valuation
|
Metric
|
HAE
|
MDT
|
|---|---|---|
Price/Earnings (Normalized) | 20.83 | 15.27 |
Price/Book Value | 5.67 | 2.20 |
Price/Sales | 3.60 | 2.96 |
Price/Cash Flow | 15.95 | 12.40 |
Price/Earnings
HAE
MDT
Financial Strength
|
Metric
|
HAE
|
MDT
|
|---|---|---|
Quick Ratio | 1.64 | 1.29 |
Current Ratio | 2.95 | 2.07 |
Interest Coverage | 5.36 | 10.12 |
Quick Ratio
HAE
MDT
Profitability
|
Metric
|
HAE
|
MDT
|
|---|---|---|
Return on Assets (Normalized) | 9.61% | 8.31% |
Return on Equity (Normalized) | 27.33% | 15.59% |
Return on Invested Capital (Normalized) | 12.36% | 10.57% |
Return on Assets
HAE
MDT
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|Dg$TGs | LOCK|&t<f | $167B | |||
| Medtronic PLC
MDT
| LOCK|>F#?stw | LOCK|kn?N | $111B | |||
| Stryker Corp
SYK
| LOCK|Nj$V<mzF | LOCK|Md | $105B | |||
| Boston Scientific Corp
BSX
| LOCK|$RvG<D | LOCK|sbH@ | $63B | |||
| Edwards Lifesciences Corp
EW
| LOCK|X^$g?x!g | LOCK|XK?? | $49B | |||
| DexCom Inc
DXCM
| LOCK|GmKr@%<g | LOCK|S&#% | $33B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|??!Kr$ | LOCK|^> | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|!$ | LOCK|<D | $23B | |||
| Steris PLC
STE
| LOCK|Y%>>Jg | LOCK|#H$?l | $20B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|N%#pwws% | LOCK|?K | $17B |
United States